Kanhaiya Lal Poddar

Kanhaiya Lal Poddar

Auto-generated profile, based on publicly available information

Kanhaiya Lal Poddar

Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in JACC
Verified
Journal Article
Closed access
SGSachin S. Goel
Sachin S. Goel
NBNavkaranbir Bajaj
Navkaranbir Bajaj
BABhuvnesh Aggarwal
Bhuvnesh Aggarwal
SGSupriya Gupta
Supriya Gupta
KPKanhaiya Lal Poddar
Kanhaiya Lal Poddar
SKSamir R. Kapadia
Samir R. Kapadia

30 June 2009 in Circulation
Verified
Journal Article
Closed access
KCKang-Yin Chen
Kang-Yin Chen
SRSeung-Woon Rha
Seung-Woon Rha
YLYong-Jian Li
Yong-Jian Li
KPKanhaiya L. Poddar
Kanhaiya L. Poddar
ZJZhe Jin
Zhe Jin
SPSeung Jung Park
Seung Jung Park
Background— Whether triple antiplatelet therapy is superior or similar to dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention in the era of drug-eluting stents remains unclear. Methods and Results— A total of 4203 ST-segment elevation myocardial infarction patients who underwent primary percutaneous coronary intervention with drug-eluting stents were analyzed retrospectively in the Korean Acute Myocardial Infarction Registry (KAMIR). They received either dual (aspirin plus clopidogrel; dual group; n=2569) or triple (aspirin plus clopidogrel plus cilostazol; triple group; n=1634) antiplatelet therapy. The triple group received additional cilostazol at least for 1 month. Various major adverse cardiac events at 8 months were compared between these 2 groups. Compared with the dual group, the triple group had a similar incidence of major bleeding events but a significantly lower incidence of in-hospital mortality. Clinical outcomes at 8 months showed that the triple group had significantly lower incidences of cardiac death (adjusted odds ratio, 0.52; 95% confidence interval, 0.32 to 0.84; P =0.007), total death (adjusted odds ratio, 0.60; 95% confidence interval, 0.41 to 0.89; P =0.010), and total major adverse cardiac events (adjusted odds ratio, 0.74; 95% confidence interval, 0.58 to 0.95; P =0.019) than the dual group. Subgroup analysis showed that older (>65 years old), female, and diabetic patients got more benefits from triple antiplatelet therapy than their counterparts who received dual antiplatelet therapy. Conclusions— Triple antiplatelet therapy seems to be superior to dual antiplatelet therapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with drug-eluting stents. These results may provide the rationale for the use of triple antiplatelet therapy in these patients.

1 March 2014 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
NBNavkaranbir Singh Bajaj
Navkaranbir Singh Bajaj
APAkhil Parashar
Akhil Parashar
SAShikhar Agarwal
Shikhar Agarwal
NSNishtha Sodhi
Nishtha Sodhi
KPKanhaiya Lal Poddar
Kanhaiya Lal Poddar
SKSamir R. Kapadia
Samir R. Kapadia

1 May 2011 in The American Journal of Cardiology
Verified
Journal Article
Closed access
SBSripal Bangalore
Sripal Bangalore
SKSunil Kumar
Sunil Kumar
KPKanhaiya L. Poddar
Kanhaiya L. Poddar
SRSureshkumar Ramasamy
Sureshkumar Ramasamy
SRSeung-Woon Rha
Seung-Woon Rha
DFDavid P. Faxon
David P. Faxon

1 June 2013 in The American Journal of Medicine
Verified
Journal Article
Closed access
NBNavkaranbir S. Bajaj
Navkaranbir S. Bajaj
SAShikhar Agarwal
Shikhar Agarwal
ARAnitha Rajamanickam
Anitha Rajamanickam
APAkhil Parashar
Akhil Parashar
KPKanhaiya Lal Poddar
Kanhaiya Lal Poddar
SKSamir R. Kapadia
Samir R. Kapadia

21 March 2014 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
AKAmar Krishnaswamy
Amar Krishnaswamy
APAkhil Parashar
Akhil Parashar
SAShikhar Agarwal
Shikhar Agarwal
DMDhruv K. Modi
Dhruv K. Modi
KPKanhaiya L. Poddar
Kanhaiya L. Poddar
SKSamir R. Kapadia
Samir R. Kapadia